<?xml version="1.0" encoding="UTF-8" standalone="no"?><information><Cell><NavigationPath><Head00>Dose</Head00><Stub><StubValue>I180/5-FU400–600</StubValue></Stub><HeaderValue>Maximum toxicity/grade Nonhaematologic G 1</HeaderValue></NavigationPath><value>7</value><CellType>Numeric</CellType></Cell><Table><TableType>Matrix</TableType><tableName>Toxicity related to the combination of irinotecan/5-FU/gefitinib by dose</tableName><tableOrder>Table 2</tableOrder><tableFooter>Gefitinib dose was 250 mg daily and it was not reduced. 5-FU=5-fluorouracil.aNumber of patients who received the given irinotecan and 5-FU doses on cycle 1.bNumber of patients who received the given irinotecan and 5-FU doses on cycle 1 plus as reductions in subsequent cycles.</tableFooter></Table><Document><DocumentTitle>A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer</DocumentTitle><PMC>2361767</PMC></Document></information>